

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Yongkun Sun, Wei Niu, Feng Du, Chunxia Du, Shuting Li, Jinwan Wang, Li Li, Fengqing Wang, Yu Hao, Chuan Li and Yihebal Chi

Journal of Hematology & Oncology (DOI 10.1186/s13045-016-0332-8)

Additional file 1




Fig. S1. Waterfall plot of best-percent change in target lesions from baseline for the 19 patients who had target lesions on the basis of investigator assessment